BCYC:NSD-Bicycle Therapeutics plc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 20.40

Change

+0.49 (+2.46)%

Market Cap

USD 0.44B

Volume

0.03M

Average Target Price

USD 27.25 (+33.58%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. Bicycle Therapeutics plc has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. The company was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-1.37 (-0.63%)

USD56.65B 21.08 16.42
REGN Regeneron Pharmaceuticals, Inc

-17.51 (-3.34%)

USD55.87B 20.76 16.02
MRNA Moderna, Inc

-2.47 (-2.44%)

USD39.98B N/A N/A
SGEN Seagen Inc

-3.44 (-2.05%)

USD30.08B 65.69 65.81
ALXN Alexion Pharmaceuticals, Inc

+0.50 (+0.41%)

USD26.83B 28.36 26.40
RPRX Royalty Pharma plc

-0.62 (-1.54%)

USD25.13B 23.05 9.48
BNTX BioNTech SE

-4.63 (-4.35%)

USD25.06B -99,999.99 N/A
BGNE BeiGene, Ltd

-17.60 (-6.43%)

USD24.70B N/A N/A
GMAB Genmab A/S

-0.81 (-2.25%)

USD23.92B 26.59 2.65
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing BCYC

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 116.33% 86% B 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 116.33% 86% B 90% A-
Trailing 12 Months  
Capital Gain 137.21% 86% B 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 137.21% 86% B 91% A-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 22.39% N/A N/A 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 22.39% N/A N/A 79% C+
Risk Return Profile  
Volatility (Standard Deviation) 44.11% N/A N/A 27% F
Risk Adjusted Return 50.76% N/A N/A 71% C-
Market Capitalization 0.44B 59% F 53% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 1,839.00 2% F 1% F
Price/Book Ratio 4.01 50% F 34% F
Price / Cash Flow Ratio -15.36 74% C 84% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -37.08% 72% C- 26% F
Return on Invested Capital -222.87% 8% F 3% F
Return on Assets -17.33% 73% C 21% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 3.99 56% F 44% F
Short Percent N/A N/A N/A N/A N/A
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.